Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Entrada Therapeutics' Depreciation and Depletion rose 3333.33% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 2236.31%. This contributed to the annual value of $3.8 million for FY2024, which is 3375.57% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Depreciation and Depletion of $1.2 million as of Q3 2025, which was up 3333.33% from $1.1 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Depreciation and Depletion high stood at $1.2 million for Q3 2025, and its period low was $400000.0 during Q1 2022.
  • Over the past 4 years, Entrada Therapeutics' median Depreciation and Depletion value was $800000.0 (recorded in 2023), while the average stood at $777133.3.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 7264.33% in 2024, then skyrocketed by 128.48% in 2025.
  • Entrada Therapeutics' Depreciation and Depletion (Quarter) stood at $500000.0 in 2022, then skyrocketed by 47.2% to $736000.0 in 2023, then soared by 35.87% to $1.0 million in 2024, then grew by 20.0% to $1.2 million in 2025.
  • Its Depreciation and Depletion was $1.2 million in Q3 2025, compared to $1.1 million in Q2 2025 and $946000.0 in Q1 2025.